Performance evaluation of a rapid multiplex point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 Antigen and Flu A/B
13 Oct 2022In this application note, the performance of the LumiraDx SARS-CoV-2 & Flu A/B Test was evaluated versus RT-PCR using anterior nasal swabs from symptomatic patients. The LumiraDx SARS-CoV-2 & Flu A/B Test is an automated, rapid, microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
Related Products
Request Quote for All Products
SARS-CoV-2 Ab Test
LumiraDxThe LumiraDx SARS-CoV-2 Ab Test is a microfluidic immunofluorescence assay for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform the Test delivers rapid results at the point of care.
LumiraDx Platform
LumiraDxNext-generation point of care diagnostic platform - Next-generation microfluidic technology on the LumiraDx Platform enables lab-comparable performance across a broad menu of diagnostic assays.